Abstract
Purpose
Intravenous (i.v.) vinorelbine (VRL) generally given on days 1 and 8 of an every three-week cycle in combination with paclitaxel (PTX) is an effective option for the treatment of metastatic breast cancer (MBC). In an effort to improve both patient and chemotherapy unit convenience, oral VRL was used at equivalent doses of i.v. VRL.
Patients and methods
The maximal tolerated dose (MTD) was determined during the first cycle of oral VRL given on days 1 and 8 or 15 and PTX infused over 3 h on day 1 every 3 weeks, maximum of 6 cycles. The dose of oral VRL was escalated from 60 to 80 mg/m2 in 10 mg/m2 increments. Paclitaxel was administered at 110 and then 135 mg/m2. The combination regimen was given as first-line chemotherapy of MBC. Three to six patients per cohort were treated.
Results
Twenty-two patients were treated in the first four cohorts (oral VRL/PTX): 60/110, 70/110, 80/110 and 80/135. In cohort 4, seven patients were treated, one patient being non-evaluable for MTD, three of them presented a dose-limiting toxicity (DLT) consisting of febrile neutropenia and neutropenic infection. Therefore 80/135 was the MTD. Because 36% of oral VRL administrations on day 8 were delayed to day 15 at 80/110, two additional cohorts were tested: in cohort 5, oral VRL 60 mg/m2 on days 1 and 15 and PTX 135 mg/m2 on day 1 and in cohort 6, oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1, every 3 weeks. In cohort 5, six out of eight patients had DLTs: omission of oral VRL on day 15 for five patients, grade 4 neutropenia >7 days for another one. Therefore the recommended dose (RD) for further clinical testing was oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1 of an every 3-week cycle. Two of the three evaluable patients treated at the RD had a partial response. The pharmacokinetics of VRL and PTX is being analysed and will be further presented in a separate publication.
Conclusions
This phase I study has determined the doses of oral VRL and PTX to be used in combination for the benefit of the patient and of the chemotherapy unit in term of nurse’s workload. The recommended regimen of oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1 given every 3 weeks will be further tested in phase II.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643–1649
Gridelli C, Manegold C, Mali P et al (2004) Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 40:2424–2431
Bourgeois H, Vermorken J, Dark G at al (2005) Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients. J Clin Oncol abstract 2028
Martin M, Casado A, Segura PD et al (2000) Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11:85–89
Romero Acuna L, Langhi M, Perez J et al (1999) Vinorelbine and paclitaxel as first line chemotherapy in metastatic breast cancer. J Clin Oncol 17:74–81
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Eng J Med 328:1323–1332
WHO handbook for reporting results of cancer treatment (1979) World Health Organisation, Geneva
EORTC manuel for clinical research in breast cancer (2004) EORTC Breast Cancer Cooperative Group, Hambourg
Culine S, Roch I, Pinguet F, Romieu G, Bressolle F (1999) Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patient previously exposed to anthracyclines. Int J Oncol 14:999–1006
Tortoriello A, Facchini G, Caponigro F et al (1998) Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47:91–97
Ibrahim NK, Buzdar AU, Valero V et al (2001) Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91:664–671
Vici P, Amodio A, Di Lauro L et al (2000) First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 58:3–7
Polyzos A, Tsavaris N, Kosmas C et al (2003) Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. J Chemother 15:607–612
Cocconi G, Mambrini A, Quarta M et al (2000) Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 88:2731–2738
Spano JP, Bouillet T, Boaziz C et al (2004) Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol 27:317–321
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delva, R., Pienkowski, T., Tubiana, N. et al. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 59, 703–709 (2007). https://doi.org/10.1007/s00280-006-0324-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-006-0324-4